Pharma Focus Asia
KP - Sustainable Packaging Solutions

CARsgen Announces Opening of CAR-T Cell Manufacturing Facility in Shanghai


Shanghai-based CARsgen Therapeutics (Carsgen) announced the opening of CAR-T cell manufacturing facility in Shanghai to support CARsgen clinical programs.


CAR-T cell manufacturing facility is in strict compliance with current good manufacturing procedure (cGMP) regulations of China Food and Drug Administration (CFDA).

The 33, 000-square-foot facility features state-of-art capabilities to manufacture vectors and CAR-T cells to support CARsgen clinical programs.

This facility marks a significant milestone of CARsgen as it has embedded the leading expertise and insights into CAR-T cell manufacturing.

CARsgen Therapeutics (CARsgen) has developed a strong CAR-T portfolio for treatment of many solid tumors including liver cancer, lung cancer, gastric cancer, pancreatic cancer and so on.

CARsgen is planning to submit about 5 Investigational New Drug (IND) applications to CFDA and get at least one IND approval from US FDA by the end of 2018, all requiring a reliable supply of clinical-quality CAR-T cells.


NameCARsgen Therapeutics (CARsgen)
LocationShanghai, China
TypeNew Manufacturing Facility
Parties InvolvedCARsgen Therapeutics
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?